Date: September 08, 2026
Financial Results (Standalone)
Quarter Ended June 30, 2026 (Q1 FY2027)
- Revenue from operations: ₹335.32 million
- Other income: ₹46.68 million
- Total Income: ₹382.00 million
- Total Expenses: ₹364.89 million
- Profit before tax: ₹17.11 million
- Tax expenses: ₹6.77 million
- Profit after tax: ₹10.34 million
- Other comprehensive income/(loss): ₹(0.73) million
- Total comprehensive income: ₹10.11 million
- Basic EPS: ₹0.03
- Diluted EPS: ₹0.03
Comparative Figures
- Q1 FY2026 Profit after tax: ₹48.97 million
- Q4 FY2026 Profit after tax: ₹86.06 million
- FY2026 Profit after tax: ₹366.16 million
Balance Sheet Highlights
- Paid up Equity Share Capital: ₹863.86 million (Face Value: ₹2 per share)
- Other Equity excluding Revaluation Reserve: ₹7,736.41 million (as of March 31, 2026)
Financial Results (Consolidated)
Quarter Ended June 30, 2026 (Q1 FY2027)
- Revenue from operations: ₹4,757.09 million
- Other income: ₹76.46 million
- Total Income: ₹4,833.55 million
- Total Expenses: ₹3,782.71 million
- Profit before tax: ₹1,050.84 million
- Tax expenses: ₹164.91 million
- Profit after tax: ₹885.93 million
- Other comprehensive income/(loss): ₹(5.81) million
- Total comprehensive income: ₹880.12 million
- Profit attributable to owners of the parent: ₹825.07 million
- Profit attributable to non-controlling interest: ₹60.86 million
- Basic EPS: ₹2.05
- Diluted EPS: ₹2.05
Comparative Figures
- Q1 FY2026 Profit after tax: ₹655.06 million
- Q4 FY2026 Profit after tax: ₹767.78 million
- FY2026 Profit after tax: ₹2,735.57 million
Board Meeting Outcomes
The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 were reviewed by the Audit Committee on August 03, 2026 and approved by the Board of Directors at its meeting held on August 03, 2026.
Expansion / Capex
- The Company launched a 350-bedded advanced multi-super specialty hospital at Panchkula on April 10, 2026, equipped with advanced diagnostics, modular operation theatres, critical care infrastructure, delivering comprehensive care across key specialties including oncology, neurosciences, orthopaedics, cardiology, and critical care including robotic-assisted procedures.
- Umkal Healthcare Private Limited, the wholly owned subsidiary, proposed expansion of its existing 225-bed Park Hospital in Palam Vihar, Gurugram, with addition of 100 new beds. The newly expanded facility will be branded as "Park Hospital Platinum" with proposed completion by November 2026. Overall cost: approximately ₹250 million, funded from internal accruals.
- RGS Healthcare Limited, a step-down subsidiary, proposed expansion of its Mohali unit from 350 beds to 500 beds. Overall cost: approximately ₹400 million, funded through internal accruals.
M&A / Stake Purchase
- Subsequent event: The Company successfully acquired 80% shareholding of V3 Healthcare Private Limited on July 31, 2026, which operates a multi-super speciality hospital "The Medicity Hospital - Rudrapur, Uttaranchal" with capacity of 330 beds. Remaining 20% will be acquired by April 30, 2030. Overall acquisition cost: approximately ₹1,770 million. V3 Healthcare became a subsidiary, and the hospital was launched on August 2, 2026.
- Aggarwal Hospital and Research Services Private Limited, a wholly owned subsidiary, divested its entire 55% shareholding in Devina Derma Private Limited for consideration of ₹0.60 million on June 05, 2026. Devina Derma ceased to be a subsidiary as a strategic management decision.
Subsidiary Updates
- Park Medicentres and Institutions Private Limited incorporated a wholly owned subsidiary "Healplus Medical Services Private Limited" (CIN: U47721DC2026PTCA71594) on May 20, 2026. The new subsidiary has not commenced business operations as of June 30, 2026.
- The consolidated results include 19 subsidiaries reviewed by other auditors and 2 subsidiaries reviewed by management.
IPO Proceeds Utilization
Utilization of IPO proceeds as of June 30, 2026 (₹ in millions):
| Purpose | Amount Raised | Amount Utilized | Balance |
| Outstanding borrowings availed by Company and Subsidiaries | 605.00 | 195.19 | 409.81 |
| Funding capital expenditure for development of new hospital by Subsidiary Park Medicity (NCR) Private Limited | 274.59 | 36.08 | 238.51 |
| Funding capital expenditure for purchase of medical equipment by Company and Subsidiaries | 2,453.18 | 2,453.18 | - |
| Unidentified inorganic acquisitions and general corporate purposes | 7,132.77 | 6,484.45 | 648.32 |
| Issue expenses towards IPO | 567.23 | 567.23 | - |
| Grand Total | 7,700.00 | 7,051.68 | 648.32 |
There is no deviation in the utilization of proceeds from the objects stated in the offer document.
Investor Relations
- During the quarter ended June 30, 2026, the Company did not receive any investor complaints.
- No complaints were pending resolution as on June 30, 2026.